Education
About Us
Working with TipRanks
Follow Us
Akeso, Inc. (HK:9926)
:9926
9926 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$26.45 - HK$78.75
Previous CloseN/A
Volume3.49M
Average Volume (3M)11.77M
Market Cap
HK$66.96B
Enterprise ValueHK$29.25B
Total Cash (Recent Filing)¥1.33B
Total Debt (Recent Filing)¥1.47B
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding897,575,200
10 Day Avg. Volume12,774,298
30 Day Avg. Volume11,765,034
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$75.57Price Target Upside1.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Akeso, Inc. News
PremiumCompany Announcements
Akeso, Inc. Reports Significant Revenue Decline for 2024
PremiumCompany Announcements
Akeso, Inc. Schedules Board Meeting to Approve Annual Results
PremiumCompany Announcements
Akeso’s Immunotherapy Drugs Join China’s Reimbursement List
PremiumCompany Announcements
Akeso, Inc. Raises HK$1.924 Billion Through Share Placement
PremiumCompany Announcements
Akeso, Inc. Aims to Raise HK$1.94 Billion in Share Placement
PremiumCompany Announcements
Akeso, Inc.’s New Cholesterol Drug Approved in China
PremiumCompany Announcements
Akeso’s Breakthrough Drug Wins Approval for Gastric CancerPremiumCompany Announcements
Akeso’s Ivonescimab Shows Promise in NSCLC Treatment---
Bulls Say, Bears Say
Bulls Say
M&A And Licensing DealsRecent M&A/licensing deals suggest increasing buy-in of the drug class from the overseas biopharma space.
Product PortfolioRising interest and commitment from leading oncology MNCs strengthen the thesis of notable global commercial upside from Akeso's portfolio of differentiated bispecific assets.
Bears Say
Early Stage Drug DevelopmentThe deal between Merck and LaNova suggests major potential for the drug class despite the early-stage status of LM-299.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.30%
Mutual Funds
― Other Institutional Investors
91.26% Public Companies and
Individual Investors
9926 FAQ
What was Akeso, Inc.’s price range in the past 12 months?
Akeso, Inc. lowest stock price was HK$26.45 and its highest was HK$78.75 in the past 12 months.
What is Akeso, Inc.’s market cap?
Akeso, Inc.’s market cap is HK$66.96B.
When is Akeso, Inc.’s upcoming earnings report date?
Akeso, Inc.’s upcoming earnings report date is Aug 27, 2025 which is in 148 days.
How were Akeso, Inc.’s earnings last quarter?
Akeso, Inc. released its earnings results on Mar 30, 2025. The company reported -HK$0.35 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.35.
Is Akeso, Inc. overvalued?
According to Wall Street analysts Akeso, Inc.’s price is currently Undervalued.
Does Akeso, Inc. pay dividends?
Akeso, Inc. does not currently pay dividends.
What is Akeso, Inc.’s EPS estimate?
Akeso, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akeso, Inc. have?
Akeso, Inc. has 897,575,200 shares outstanding.
What happened to Akeso, Inc.’s price movement after its last earnings report?
Akeso, Inc. reported an EPS of -HK$0.35 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.897%.
Which hedge fund is a major shareholder of Akeso, Inc.?
Currently, no hedge funds are holding shares in HK:9926
---
Akeso, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.91%
12-Months-Change
Fundamentals
Return on Equity
-14.20%
Trailing 12-Months
Asset Growth
15.62%
Trailing 12-Months
Company Description
Akeso, Inc.
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
---
9926 Stock 12 Month Forecast
Average Price Target
HK$75.57
▲(1.30% Upside)
Technical Analysis
Shanghai Fosun Pharmaceutical (Group) Co
―
Wuxi Biologics (Cayman)
―
Viva Biotech Holdings
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Best Analysts Covering 9926
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+82.17%
reiterated a buy rating 9 months ago
Copying Tony Ren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +82.17% per trade.
---